Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer

计划入组 212 人 · 首次发布于 2011 年 9 月 28 日

Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer

计划入组 18 人 · 首次发布于 2014 年 12 月 8 日

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

计划入组 17 人 · 首次发布于 2016 年 9 月 15 日

Bacillus calmette-guerin substrain russian BCG-I live antigen(VERITY-BCG)

BCG vaccine

Nadofaragene firadenovec-vncg(Adstiladrin)

Zhejiang Jingxin Pharmachutical Co.,ltd.

China

Nutrin GmbH

Germany

PALMETTO RETINA CENTER, LLC

United States

CG Oncology's Cretostimogene Shows Positive Phase 3 Results in Bladder Cancer

Ferring Advances Nadofaragene Firadenovec Clinical Program in Urothelial Cancers

Durvalumab Plus Vaccine Therapy Shows Promise in BCG-Unresponsive NMIBC